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Pulmonary drug deliveryThe development of clinically acceptable albumin-based nanoparticle formulations for use in pulmonary drug
delivery has been hindered by concerns about the toxicity of nanomaterials in the lungs combined with a lack
of information on albumin nanoparticle clearance kinetics and biodistribution. In this study, the in vivo biocom-
patibility of albumin nanoparticleswas investigated following a single administration of 2, 20, and 390 μg/mouse,
showing no inﬂammatory response (TNF-α and IL-6, cellular inﬁltration and protein concentration) compared to
vehicle controls at the two lower doses, but elevated mononucleocytes and a mild inﬂammatory effect at the
highest dose tested. The biodistribution and clearance of 111In labelled albumin solution and nanoparticles
over 48 h following a single pulmonary administration tomice was investigated by single photon emission com-
puted tomography and X-ray computed tomography imaging and terminal biodistribution studies. 111In labelled
albumin nanoparticles were clearedmore slowly from the mouse lung than 111In albumin solution (64.1 ± 8.5%
vs 40.6 ± 3.3% at t = 48 h, respectively), with signiﬁcantly higher (P b 0.001) levels of albumin nanoparticle-
associated radioactivity located within the lung tissue (23.3 ± 4.7%) compared to the lung ﬂuid (16.1 ± 4.4%).
Low amounts of 111In activity were detected in the liver, kidneys, and intestine at time points N24 h indicating
that small amounts of activity were cleared from the lungs both by translocation across the lungmucosal barrier,
aswell asmucociliary clearance. This study provides important information on the fate of albumin vehicles in the
lungs, which may be used to direct future formulation design of inhaled nanomedicines.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The potential for nanoparticles to provide controlled drug delivery to
the lungs is well recognised [1,2]. The beneﬁts of using nanoparticles as
oppose tomicron-scale carriers in the lungs include the ability to reduce
unwantedmacrophage uptake [3], modify dissolution rates particularly
of poorly soluble drugs [4], and to improve deposition and retention
proﬁles in the lungs [5,6]. However, there has been little translation
of pulmonary nanomedicine from the research bench to the clinic,
not least because of safety concerns associated with inhalation of
nanoparticulate matter [7,8].
Chronic exposure to certain types of nanoparticles has been associated
with inﬂammation, ﬁbrosis and the release of pro-thrombotic mediators
which can lead to induced vascular thrombosis and cardiac arrest [9].
In addition, inhaled nanoparticles have been observed to pass through
the lung epithelium and enter the systemic circulation prompting fears
concerning accumulation in secondary organs [10]. The type and extent. This is an open access article underof toxicity elicited by a particulate nanocarrier has been linked to a variety
of factors including particle size, composite material, surface charge and
reactivity, hydrophobicity, and aspect ratio [11–15]. In addition to acute
inﬂammatory response, insoluble nanoparticles are associated with long
retention times in the lungs making accumulation associated toxicity
upon repeated dosing a concern [16]. Any candidate as a medical nano-
particle formulation for pulmonary administration must therefore be
inert, biodegradable, and biocompatible both at the nanoscale and in
terms of breakdown products [17,18].
Albumin, both in its native form and when fabricated into nano-
particles, is used with great success and versatility as a drug carrier
in injected formulations [19,20]. An albumin nanoparticle based-
formulation, Abraxane®, is used clinically to deliver the highly po-
tent anti-cancer drug, paclitaxel, without the need for stabilizing
agents [21]. With regard to its suitability for pulmonary drug delivery,
albumin is an abundant component of lung lining ﬂuid [22], with a con-
centration ~10% of that found in serum [23]. As albumin is naturally
present within the lungs, endogenous transport and metabolic processes
exist which could be utilised for drug release [24,25] and alleviatethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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assembling human serum albumin nanoparticles have been recently de-
veloped as a novel vehicle for a combination formulation consisting of
doxorubicin and tumour necrosis factor related apoptosis-inducing ligand
(TRAIL). This formulationwas shown to signiﬁcantly reduce lung tumour
size following pulmonary administration in amousemodel of lung cancer
[26]. In addition, the 99mTc-labelled aggregated albumin complex 99mTc-
Nanocoll® has been used extensively for diagnostic imaging in nuclear
medicine and todeterminepulmonarydepositionpatterns inhuman sub-
jects following aerosol inhalation [27,28].
Despite the interest in developing albumin nanoparticles for pul-
monary drug delivery, information on the safety, clearance kinetics,
and biodistribution of the albumin vehicle is currently lacking. It is
recognised that the highest achievable therapeutic dose of an in-
haled nano-formulation may be limited by the highest tolerated
dose of the nanomaterial rather than that of the therapeutic com-
pound. Secondly, estimation of nano-formulation pharmacokinetics
and administration frequency must include an understanding of the
vehicle clearance kinetics as well as that of the therapeutic agent [29].
Therefore, the aim of this study was to evaluate the dose-dependent
biocompatibility of two albumin vehicles (solution and nanoparti-
cles) following a single pulmonary administration to mice in vivo.
Clearance of 111indium-diethylene triamine pentaacetic acid (111In-
DTPA) radiolabelled albumin vehicles from the lungs of mice was also
measured longitudinally using combined single photon emission com-
puted tomography andX-ray computed tomography (SPECT/CT) imaging
over 48 h. Local distribution of albumin and albumin nanoparticles in the
lung, as well as accumulation in secondary organs was also measured
using terminal end-point organharvest biodistribution studies. The provi-
sion of information on albumin vehicle biocompatibility, clearance kinet-
ics and biodistribution will ultimately enable formulation scientists to
decide whether the use of an albumin vehicle is an appropriate tool to
achieve a desired pharmacokinetic proﬁle for an intended therapy prior
to engaging in lengthy formulation optimisation studies. Secondly,
knowledge of the maximum tolerated dose of the albumin vehicle will
enable estimations of the theoretical drug loading requirements, provid-
ing the basis for a go/no-go decision-making tool in nano-formulation
design.
2. Methods
2.1. Materials and reagents
Bovine serum albumins (laboratory grade albumin, albumin tissue
culture grade and low endotoxin, essentially IgG free albumin) were
purchased from Sigma (Dorset, UK). S-2-(4-Isothiocyanatobenzyl)-
diethylenetriamine pentaacetic acid (p-SCN-Bn-DTPA) was purchased
from Macrocyclics (Dallas, USA). 111InCl3 was purchased from
MallinckrodtMedical Inc. (Petten, Netherlands). Phosphate buffered sa-
line (PBS) tablets were purchased from Oxoid (Basingstoke, UK) and
prepared using ultrapure water according to the manufacturer's in-
structions. Foetal bovine serum was purchased from Life Technologies
(USA). Diethylenetriamine pentaacetic acid (DTPA) and ammonium ace-
tate were purchased from Fluka (UK). Sodium hydroxide (NaOH) and
Tris(hydroxymethyl)aminomethane (Tris) were purchased from
Fisher Scientiﬁc (Loughborough, UK). Glutaraldehyde (50% vol/vol in
water) was purchased from Aldrich (UK). Ethanol was purchased from
VWR (Radnor, USA).
2.2. Animals
All experiments were conducted in accordance with the United
Kingdom Animal Scientiﬁc Procedures Act, 1986 and were approved
by the ethics committee of Kings College, London. All in vivo experi-
ments were performed with Male BALB/C mice (6–8 weeks of age;
approx 20–26 g) which were purchased from Harlan, UK. Mice werehoused in rooms maintained at a constant temperature (21 ± 2 °C)
and humidity (55 ± 15%) with a 12 hour light–dark cycle. Animals
had food (SDS, UK) and water available ad libitum and were allowed
1 week acclimatisation period before use.
2.3. Nanoparticle preparation and characterization
Nanoparticles were prepared using a desolvation method as widely
reported in the literature [30,31]. In brief, bovine serum albumin
(100mg) was dissolved in 0.01M Tris HCl buffer (1mL) and the pH ad-
justed to 9 with 1 M NaOH. Ethanol was added drop-wise to the stirred
protein (4.0 mL, 1 mL/min). Nanoparticles were cross-linked with
10% vol/vol glutaraldehyde/water (47.2 μL) and stirred overnight at
room temperature, and puriﬁed into sterile PBS by four cycles of spin ﬁl-
tration (30 kDa molecular weight cut-off (MWCO) centrifugal ﬁlter
units, Millipore, 2400 ×g, 10 min per cycle). Nanoparticle size and
polydispersity were measured using a Zetasizer Nano Series ZS
(Malvern Instruments, Malvern, UK). Particles were diluted 1:10 in
PBS and measurements taken at 37 °C, scattering angle 173°, using
viscosity value of 0.6885 cP for the dispersant. Zeta potential was
measured in PBS at 25 °C at a concentration of 20 μg/mL. Particle
concentration was determined gravimetrically.
2.4. In vitro macrophage activation assays
Albumin nanoparticles were prepared using three grades of bovine
serum albumin: laboratory grade (N96% purity); tissue culture grade;
low endotoxin grade (all Sigma, UK). J774.A1 cells, a macrophage cell
line derived fromBALB/Cmice, were seeded in 24-well plates at a density
of 1 × 106 cells per well and incubated overnight in cell culture medium
(DMEM, 4.5 g/L glucose, 1% sodium pyruvate, 1% penicillin/streptomycin,
1% HEPES buffer and 1% L-glutamine) containing 10% (v/v) foetal bovine
serum (FBS) in a humidiﬁed 5% CO2: 95% air incubator at 37 °C. Following
incubation, cell culture medium was replaced with 200 μL of fresh medi-
um containing 4350 μg/mL of albumin nanoparticles prepared from each
BSA grade. Positive control cells were primed for 18 h with interferon-
gamma (IFN-γ) prior to incubation with 1 μg/mL lipopolysaccharide
(from Escherichia coli 0111:B4; Sigma Aldrich, UK). Untreated cells were
used as a negative control. Cells were incubated with nanoparticles for
4 h, following which 100 μL supernatant was removed and analysed to
quantify levels of interleukin-6 (IL-6), tumour necrosis factor alpha
(TNF-α) and nitric oxide. TNF-α and IL-6 release were measured using
enzyme-linked immunosorbent assay (eBioscience, conducted according
to manufacturer's instructions). Nitric oxide (NO) production was mea-
sured using the Griess reaction [32].
2.5. In vivo biocompatibility
Low endotoxin grade albumin nanoparticles were suspended
in sterile phosphate buffered saline (PBS) and administered at three
doses for biocompatibility studies, 2, 20, and 390 μg per mouse (~0.1,
1, 16 mg/kg). The doses fall within the range typically used for inhala-
tion studies of this nature [15,33,34]. Sterile PBS was used as a vehicle
control. Albumin nanoparticles were administered via oropharyngeal
aspiration (o.a.; method adapted from Lakatos et al., 2006 [35]). Brieﬂy,
anaesthetized mice (3–5% isoﬂurane, O2 ﬂow rate of 1.0 mL/min) were
administered a droplet of 25 μL of albumin nanoparticle suspension in
sterile saline (2, 20 or 390 μg/mouse) applied to the posterior base of
the pharynx, where it was readily aspirated. Mice were euthanized hu-
manely after 24 h with an intraperitoneal (i.p.) injection of urethane
(500 mg/mL in physiological saline, 0.3 mL/mouse). The lungs were
lavaged with 3 × 0.5 mL sterile physiological saline. The total number of
cells in the lavage ﬂuid was counted using a Neubauer haemocytometer
(Fisher Scientiﬁc, Loughborough, UK). Diffquick® (DADE Behring,
Marburg, Germany) staining was used to perform differential cell counts
in 100 cells permouse. Eosinophils were not observed in the BAL ﬂuid, so
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tent in BALwas quantiﬁedusing aQuick Start™Bradford ProteinAssay kit
(Bio-Rad, Hemel Hempstead, UK) according to the manufacturer's in-
structions. Levels of BAL IL-6 and TNF-αwere quantiﬁed using a mouse
IL-6 or TNF-α ELISA kit (Thermo Scientiﬁc, Rockford, USA) according to
the manufacturer's instructions. Tissue histology was performed as de-
scribed previously by Egger et al. [36]. In brief, three transverse sections
(~2 mm thick) were cut through the left lung (superior, median, and
caudal regions), which had been ﬁxed in 10% formalin for at least
one week prior to tissue processing. Lung sections were dehydrated
through ascending grades of ethanol and embedded in parafﬁn wax.
Histological slices (4 μm) were obtained from each lung section and
stained with haematoxylin and eosin (H&E) to assess general
morphology.
2.6. Preparation and serum stability of 111In labelled albumin nanoparticles
111In labelled albumin was prepared by ﬁrst synthesizing 2-(4-
isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid-conjugated
bovine serum albumin (p-SCN-Bn-DTPA-albumin), followed by label-
ling with 111In. Labelled albumin nanoparticles were prepared from
111In labelled protein using a modiﬁed, small scale desolvation method
(mini-prep). Brieﬂy, bovine serum albumin (33 mg) was dissolved in
ice cold 0.1 M sodium carbonate buffer (pH 9.2, 10 mL). p-SCN-Bn-
DTPA was dissolved in dry DMSO (3 mg/mL, 50 μM), added drop-wise
to the stirred protein solution on ice, and left to stir overnight at 4 °C.
Excess p-SCN-Bn-DTPA was removed by four cycles of spin ﬁltration
(10 k Da MWCO, 2400 ×g, 10 min and 4 °C), and buffer was replaced
by chilled ultrapure water (MilliQ, 18.2 mΩ). Prior to reaction with
111In, 10% v/v 1 M ammonium acetate buffer was added to p-SCN-Bn-
DTPA-albumin solution to adjust the pH to 6.6 for radiolabelling.
111InCl3 (1 part) was diluted with 2 parts ammonium acetate buffer
(0.5 M, pH 6.6), then incubated with an equal volume of p-SCN-Bn-
DTPA-albumin for 30 min at 37 °C [37]. Any unbound activity was
removed by at least 5 cycles of spin ﬁltration (30 kDa, 5000 ×g, 3 min).
Radiolabelling efﬁciency was calculated from activity measured in wash-
ings, bound to the ﬁlter and in ﬁnal recovered product. 111In albumin for
administration to mice as a solution was prepared in sterile PBS.
Nanoparticles were prepared bymixing 100 μL 111In-labelled p-SCN-
Bn-DTPA-albumin (111In albumin) with Tris HCl (0.1 M) and NaOH
(1 M), followed by drop-wise addition of a 4-fold volume of ethanol
and rotating (500 rpm). 10% (w/v) glutaraldehyde in water was added
followed by overnight incubation under rotation (500 rpm) and puriﬁca-
tion by spin ﬁltration (100 kDa, 5000×g, 3min). Radiolabelling efﬁciency
was calculated from activitymeasured in the total waste, ﬁlters and in the
recoverable product. Radiolabel stability in biological media was evaluat-
ed by incubating aliquots of 111In albumin nanoparticles and solution
with foetal bovine serum (FBS) at 37 °C for 48 h (n = 5). At t = 24 and
48 h, 250 μL samples were removed, centrifuged 3 min at 10000 ×g
using 30 kDa MWCO spin ﬁlters (Millipore), the supernatant and ﬁltrate
collected and activity in each measured using a gamma counter (1282
Compugamma Laboratory Gamma Counter, LKB Wallac) to determine
the proportion of activity leached from the sample.
2.7. SPECT/CT 3D imaging
Healthymale BALB/Cmicewere anaesthetizedwith isoﬂurane (level
2–2.5, O2 ﬂow rate 0.8 mL/min), and administered 25 μL of either 111In
albumin nanoparticles or solution in sterile PBS (300–380 μg per
mouse, activity matched 1–3 MBq per mouse, n = 3 per treatment
group) via o.a. administration. Mice were placed in a prone position
on the NanoSPECT/CT PLUS preclinical animal scanner (Mediso,
Hungary) and imaged immediately post-administration. CT images
were obtained with 55 kVP X-ray source, 500 ms exposure time in
240 projections, with a pitch of 1 over approximately 8min. Immediate-
ly following CT scan, SPECT images were acquired using an exposuretime of 1200 s, obtained over 60 projections (60 s per projection) and
equippedwith a 4-head scanner eachwith nine 1mmpinhole apertures
in helical scan mode with a total acquisition time of 35 min. CT images
were reconstructed in a 352 × 352 matrix using Bioscan InVivoScope
(Bioscan, USA) software, whereas SPECT images were reconstructed in
a 256 × 256 matrix using HiSPECT (ScivisGmbH, Bioscan). Images
were fused and analysed using InVivoScope (Version 1.44, Bioscan).
Further SPECT/CT scans were acquired at t = 4 h, 24 h, and 48 h post-
dosing. Quantiﬁcation of activity in organs of interest was performed
using the quantiﬁcation tool of the InVivoScope software, selecting
each organ (lungs, mouth, trachea, liver, intestines) as a region of inter-
est (ROI). Activity in lungs during theﬁrst scan (t=0.25h)was taken as
100% activity for clearance kinetics calculations. Mice dosed with 111In-
DTPA in PBS were used as controls and were treated as above with the
exception of additional images collected at t = 0, 11, 23, 35, 120, and
360min to capture the faster rate of clearance from the lung. Following
the ﬁnal scan, mice were culled by cervical dislocation and the trachea,
throat, lungs, heart, liver, intestines, spleen, kidneys, bladder, muscle,
and blood were collected for biodistribution studies.
2.8. BAL analysis and organ biodistribution studies
Mice were treated with 111In albumin nanoparticles and 111In albu-
min (180–260 μg per mouse, n = 3–4 per time point, 0.2–0.5 MBq)
via o.a. administration. At t = 4, 24, and 48 h (n = 3–5 for each treat-
ment group), mice were humanely culled and BAL ﬂuid collected as de-
scribed above. Activity was measured in a 200 μL aliquot of BAL and the
remaining ﬂuidwas centrifuged 20min at 1000 ×g. The cellular fraction
was separated from the ﬂuid phase and resuspended in PBS (1 mL).
Activity in lung tissue, whole BAL (200 μL), supernatant and cellular
fraction was measured by gamma scintigraphy. Following lung lavage,
the trachea, throat, lungs, heart, thymus, liver, intestines, spleen, kid-
neys, bladder, muscle, faeces, and blood were collected and activity
was measured using gamma scintigraphy. Activity in 5 μL aliquots of
111In albumin nanoparticles, 111In albumin and 111In DTPA preparations
used for administration were measured to allow calculation of activity
in organ as % of total dose.
2.9. Statistical analysis
BAL cell counts and differentials were analysed using GraphPad
Prism 5 software (version 5.02, GraphPad Software Inc., USA) using
Mann–Whitney test. Lung clearance data from SPECT/CT image analysis
was performed by systematic comparison of group means using two-
tailed Student's t-test (SigmaPlot version 12.0, Systat Software Inc.,
UK). BAL and lung tissue analysis was performed using Two Way
ANOVA with a post-hoc Tukey's test (SigmaPlot version 12.0, Systat
Software Inc, UK). P b 0.05 was considered signiﬁcant.
3. Results
3.1. Nanoparticle characterization and radiolabelling
As a quality control screen for endotoxin levels, nanoparticles were
prepared from lab-grade (BSA LAB; 150 ± 32 nm), tissue culture
grade (BSA TC; 171 ± 9 nm) and low endotoxin-grade (BSA LET;
108 ± 3 nm) albumin, then incubated with the murine macrophage
cell line J774.A1 followed by assessment of IL-6, TNF-α and nitric oxide
(NO). Co-treatment of selected samples with polymyxin B (PMB), an
agent known to suppress the immunostimulatory effects of LPS [38],
was used to conﬁrm LPS contamination as the likely cause of the inﬂam-
matory response. Cells exposed to albumin nanoparticles prepared from
low-endotoxin, IgG-free albumin did not release detectable levels of
IL-6, TNF-α, or NOover a 4 h incubation period (Fig. 1). All subsequent ex-
periments were therefore carried out with low endotoxin grade albumin
(referred to simply as albumin in the further text).
Fig. 1. Elevated endotoxin contaminant levels present in lab-grade (BSA LAB) and tissue culture-grade (BSA TC) albumin nanoparticles stimulated macrophage activation in vitro, as
expressed by (A) IL-6, (B) TNF-α, and (C) NO release. Low endotoxin-grade albumin nanoparticles (BSA LET) and media controls (data not shown) were non-stimulatory. Samples
labelled + PMB indicate co-treatment with polymyxin B. Data represent mean ± SD (n = 3). n.d. = below the detection limit, n.s. = P N 0.05 compared to IFN/LPS positive control.
All other samples differed signiﬁcantly from the IFN/LPS positive control (P b 0.05).
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of a reproducible size and narrow size distribution (Table 1). 111In albu-
min nanoparticles were larger with a broader particle size distribution,
comparedwith non-radiolabelled nanoparticles, as a result of necessary
modiﬁcations to the manufacturing protocol (lower volumes and initial
albumin concentrations [31]) required for successful radiolabelling. All
albumin nanoparticles exhibited a moderately negative zeta potential
in PBS (Table 1). The radiolabelling efﬁciency was 55.8 ± 21.9% with
111In albumin nanoparticle yields of 67.3± 14.1%. Serum stability studies
conﬁrmed that activity remained ﬁrmly associated with albumin (in
nanoparticles or solution) over the 48 h study period.3.2. In vivo biocompatibility
Following o.a. administration of three different doses of albumin
nanoparticles to mice, no signiﬁcant change compared to vehicle con-
trol was observed at t = 24 h with regard to the total number of BAL
cells, number of BAL polymorphonucleocytes (PMN) or BAL ﬂuid pro-
tein content or IL-6 and TNF-α levels (Fig. 2). The single exception to
this was an observed increase in BAL PMN at the highest dose of albu-
min nanoparticles.
Histopathology conﬁrmed an absence of inﬂammatory response
in tissue following administration of the lowest dose of albumin
nanoparticles (Fig. S1), with some mild cell inﬁltration (macro-
phages and monocytes) following administration of the 20 μg dose
to the mouse lung. Histopathology of lungs exposed to the highest
dose of albumin nanoparticles (390 μg) revealed minor epithelial
damage and low levels of neutrophilic inﬁltration, mirroring the ob-
servations in BAL.Table 1
Physicochemical characterization of albumin nanoparticles and serum stability of 111In-labelled al
Nanoparticle properties
Diameter (nm)
Albumin nanoparticles 108 ± 3
111In albumin nanoparticles 193 ± 110
111In label retention in FBS at 37 °C (%)
111In albumin solution
111In albumin nanoparticles3.3. SPECT/CT analysis of lung clearance and biodistribution
SPECT/CT analysis revealed that the o.a. dosing technique delivered
12.5–38.2% of 111In albumin nanoparticles and 3.4–37.7% of 111In
albumin to the lungs of mice (Fig. S2 in supplementary information).
The remainder of the dose was largely found in the mouth, trachea,
and intestines, indicating swallowing and subsequent clearance via
the digestive tract over 24 h for any non-pulmonary component
(Fig. S3 in supplementary information). SPECT/CT images showed that
111In albumin nanoparticles were retained throughout the 48 h imaging
period (Fig. 3). Quantiﬁcation of the SPECT/CT images revealed that
111In albumin nanoparticles were cleared more slowly from the lungs
than 111In albumin over the imaging period (Fig. 4). At 48 h, a signiﬁcantly
(P = 0.01) higher fraction of 111In albumin nanoparticles (64.1 ± 8.5%)
remained in the lungs compared with 111In albumin delivered as a solu-
tion (40.6 ± 3.3%).
Any 111In albumin not inhaled could be visualised passing through
the GI tract in the ﬁrst 4 h post-dosing, and was largely cleared from
the bodyby the24h time point (Figs. 3, S3). 111InDTPA controls showed
activity cleared extremely rapidly from the lungs with only 8.4% of the
inhaled dose remaining in the lungs by 3 h. 111In DTPA activity was ob-
served in the bladder and kidneys in the ﬁrst hour of scanning, indicat-
ing clearance via the urine.3.4. Organ biodistribution
Distribution of activity measured in organs at 4, 24, and 48 h post-
administration of albumin nanoparticles and albumin was in good
agreement with SPECT/CT imaging results at all time points. At 4 hbumin and albumin nanoparticles over 48 h at 37 °C. Data represent mean ± SD (n= 3–4).
P.D.I. Zeta potential (mV)
0.125 ± 0.013 −17.5 ± 1.8
0.279 ± 0.082 −14.4 ± 0.9
24 h 48 h
97.8 ± 2.1 99.4 ± 0.3
98.8 ± 0.6 97.9 ± 0.6
Fig. 2. Total cell counts, polymorphonucleocytes (PMN), protein concentration and cytokine release in BAL ﬂuid 24 h after o.a. administration of albumin nanoparticles at three dose levels.
Data represent n = 5 (n = 3–5 for PBS controls). ** P b 0.01 from PBS vehicle controls.
Fig. 3. Representative SPECT/CT images showing clearance of 111In-albumin activity from themouse lung over 48 h after administration of albumin (300–380 μg per animal) in the form of
(A) 111In albumin nanoparticles and (B) 111In albumin solution, and (C) rapid rate of clearance of the control complex 111In-DTPA from the mouse lung over 40 min.
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Fig. 4. Lung clearance proﬁles of 111In-albumin nanoparticles (●),111In-albumin solution
(▽) and 111In-DTPA (■) following o.a. administration (n = 3; mean ± SD). Data are
decay-corrected proﬁles derived from SPECT/CT images and expressed as % lung clearance
(relative to 111In activity in the lungs a t= 0). * P= 0.01 statistically signiﬁcant difference
from albumin solution.
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majority of radioactivity was observed in the lungs and the GI tract
(Fig. 5). Following this, the albumin solution was cleared from the
lungs more rapidly, with signiﬁcant albumin-associated activity found
in the intestines, liver and kidneys compared to nanoparticle-associated
activity, which remained primarily in the lungs. The overall agreement
in results between terminal end-point organ analysis and imaging studies
(e.g. slower clearance of albumin nanoparticles compared to solution, no
major organ accumulation) provides evidence to support the case for
SPECT/CT studies as a viable, animal-sparing alternative tomeasure parti-
cle distribution and fate [39].
Organ analysis following administration of 111In-DTPA was also in
agreement with SPECT/CT imaging in demonstrating the rapid clearance
of the label and chelator from the lungs directly into the bloodstream
followed by renal clearance within 3 h (Fig. S4). This rapid absorption of
111In-DTPA and concentration in the urine was in stark contrast to the
clearance proﬁles of 111In albumin in solution or particulate form,
conﬁrming that the label remained attached to albumin for the du-
ration of the in vivo experiments.
Analysis of lung tissue and BAL ﬂuid revealed signiﬁcant differences
in the location of 111In albuminwithin the lungs over 48 h after delivery
as nanoparticles compared to solution (Fig. 6). For both formulations, a
substantial fraction of albumin delivered was foundwithin the lung tis-
sue (i.e. non-recoverable by BAL) within 4 h, and increased over the
study period. Lung tissue accumulation was signiﬁcantly higher for
nanoparticulate albumin compared with albumin solution (P b 0.001)
at all time pointsmeasured. Albumin-associated 111In activity also accu-
mulatedwithin the BAL cellular fraction over time,with a 2.5-fold great-
er cellular localization of albumin nanoparticles (12.6 ± 10.4% vs 4.7 ±
1.7% for solution). At all times, the activity found in the BAL ﬂuid phase
was signiﬁcantly higher (P b 0.001) when delivered as 111In albumin so-
lution compared to 111In albumin nanoparticles.
4. Discussion
Despite the exciting opportunities they afford, safety concerns have
limited the development of nanomedicines for pulmonary use [7,40,41]
since evenmaterials that are relatively inert in the bulk scalemay be as-
sociated with toxicity when nano-sized [42,43]. However, there have
been few studies into the safety and targeting potential of putatively
well-tolerated nanoparticulate drug carriers for pulmonary delivery. In
this study, albumin nanoparticles produced little or no inﬂammatoryresponse in vitro or in mouse lungs following pulmonary delivery.
Only at the highest dose administered (390 μg/lung) did any of the
end-points return a positive signal, and this was limited to a mild
neutrophilia (6.5-fold increase in PMN compared to vehicle control),
which was signiﬁcantly lower than that reported for other ‘inert’ nano-
particle types tested in similar models. For example, PMN numbers fol-
lowing administration of 50 nm unmodiﬁed polystyrene nanoparticles
(50 μg/lung) and hydrophobic polyvinylacetate-co-alcohol nanoparti-
cles (150 nm diameter, 20 μg/lung) were ~75-fold higher than the ele-
vated PMN numbers observed for the high dose albumin nanoparticles
in this study [44]. Histopathology evaluation identiﬁedminor epithelial
damage following administration of the highest dose of particles, and
some mild cell inﬁltration was observed following administration of
20 μg/mouse which was not observed in BAL analysis. Further bio-
compatibility studies using doses between 20 and 400 μg/mouse (~1–
16 mg/kg) and particularly multiple-dose biocompatibility studies
would be the next step towards establishing a no observed adverse ef-
fect level (NOAEL) for albumin nanoparticles.
SPECT/CT imaging and post-mortem organ biodistribution studies
both showed that albumin nanoparticles remained in the lungs longer
than when delivered as a solution. The difference in particle size
between albumin in solution (~7 nm) and the nanoparticulate form
(~190 nm) provides an obvious basis for this difference in clearance
rates. In its native state, albumin can exploit endogenous mechanisms
for protein clearance from the lungs [45], which may not be accessible
to nanoparticulate albumin, due to conformation or size. Bondesson
et al. [46] determined the clearance rate of 99mTc-labelled macro-
aggregated albumin (Nanocoll®), particle size 8–80 nm, from the
human lungs (t1/2 = 8.75 h) to be considerably slower than that
which had been recorded by other groups for albumin delivered in solu-
tion (~35% cleared in 1 h) [47]. The difference in formulationwas deter-
mined to be a likely factor for the different clearance rates observed, and
may also be a reasonable explanation for the results of this study. The
absence of major nanoparticle accumulation in secondary organs
allayed concern about potential secondary toxicity which has been
raised for other nanoparticle formulations [41,48,49]. There was a
small but signiﬁcant increase in albumin-associated activity in the
liver and kidneys at 24 and 48 h post-dosing with solution compared
to treatmentwith albumin nanoparticles. This was attributed to smaller
nanoscale species (b10 nm) reaching secondary organs after adminis-
tration to the lungs through passage into the bloodstream [10].
Mucociliary clearance could not be characterized reliably within the
ﬁrst 24 h of the study, because the fraction of the lung dose cleared via
this mechanism could not be distinguished from the ~60% of the ini-
tial dose that was swallowed during o.a. administration. SPECT/CT
images showed very little GI tract signal activity at 24 and 48 h
post-administration, however, terminal end-point organ biodistribution
studies revealed low levels of activity (4–6% of that remaining in the
body) in the intestines at these time points, possibly indicating further
clearance of a fraction of the remaining lung dose via the mucociliary
route.
Clearance rate from the lungs is a major inﬂuence on both the phar-
macokinetic proﬁle of the drug administered in an inhaled nanomedicine,
as well as the potential for lung accumulation of the nanoparticle vehicle
and may depend on the physicochemical properties of the inhaled
nanomaterial. For example, Videira et al. [50] reported that ~75%
of the lung dose of solid lipid nanoparticles (200 nm) were rapidly
cleared from the lungs into lymph in rats within the ﬁrst hour
post-administration. In contrast, Liu et al. [51] reported that poly-
acrylamide nanoparticles (20–40 nm) were shown to remain pri-
marily in the lungs over 24 h. A recent study by Choi et al. [26]
observed that dye-labelled albumin nanoparticles (~200 nm)
remained in the lungs for much longer periods (N48 h). As a result
of the extended residence time of soluble and nanoparticulate albu-
min in respiratory tract, studies investigating pulmonary albumin
biodegradation must be conducted in order to ensure that multiple
Fig. 5. 111In activity measured directly inmajor organs of mice expressed as the proportion of total activity remaining in the body and each time point: t = 4 h (n= 3), 24 h (n= 3), and
48 h (n = 6). Data represent mean ± sd. *** P b 0.001; ** P b 0.01; * P b 0.05.
7A. Woods et al. / Journal of Controlled Release 210 (2015) 1–9dosing will not lead to detrimental accumulation. Unfortunately, the
experimental design used in the current study cannot provide detailed in-
sight into this question, as it is not possible to distinguish whether the
111In-albumin activity is associated with intact nanoparticles, intact pro-
tein or metabolized peptide fragments. Therefore, future studies investi-
gating albumin nanoparticle metabolism, as well as drug release, under
conditions that mimic the respiratory tract would be of particular rele-
vance to the development of these systems.
It was interesting to compare the spatial distributions of albumin
nanoparticles versus solution within the lungs over 48 h, as this is rele-
vant for therapeutic performance of inhaled nanomedicines. Substantial
levels of soluble albumin and albumin nanoparticles could be detected
within the BAL ﬂuid phase at all time points tested, although the nano-
particle fraction decreased to b2% of the lung dose by 48 h compared to
~7% soluble albumin remaining in theﬂuid phase at 48h. This observationprovides important information for controlled release strategies,whereby
prolonged drug release within compartments of the lungs is intended.
Both albumin nanoparticles (~6%) and a smaller fraction of soluble
albumin (~2%) were found within the BAL cellular fraction after 24 h,
demonstrating that alveolar macrophages and possibly neutrophils
phagocytosize albumin nanoparticles of this size and surface chemistry,
suggesting an additional clearance mechanism for these nanoparticles
apart from degradation in the lung lining ﬂuid. Finally, the majority of ra-
dioactivity in the lungwas located in lung tissuewith a notable increase in
this compartment over time. Migration of soluble and nanoparticulate al-
bumin into the tissue may result from direct uptake into epithelial cells
and/or phagocytosis by alveolar macrophages, which then migrate into
the lung interstitium [33,52]. The high tissue retention associatedwith al-
bumin nanoparticles may be useful for therapeutic regimes such as lung
cancer treatment with inhaled nanomedicines [26], which would beneﬁt
Fig. 6. Distribution of 111In-albumin within murine lungs at t = 4, 24 and 48 h after o.a. administration of 180–260 μg albumin nanoparticles or albumin solution. Plots show the radio-
activity expressed as percentage of the lung dose associated with (A) lung tissue, (B) cellular fraction or (C) BAL ﬂuid phase. P b 0.001 between 111In-albumin nanoparticles vs solution
in lung tissue and BAL ﬂuid phase across all time points as determined by two-way ANOVA. No signiﬁcant differences were observed between formulations in the BAL cellular fraction.
Data represent mean ± SD (n = 3–4).
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sue and low systemic drug exposure.
5. Conclusions
Administration of albumin nanoparticles to the lungs of mice showed
a high biocompatibility over a wide dose range, with evidence of mild in-
ﬂammation only at the highest dose tested. This data provide a useful
basis for the design of multiple dose studies with the aim of establishing
a NOAEL value for albumin vehicles. Complimentary longitudinal SPECT/
CT imaging and terminal ﬁxed end-point organ biodistribution studies
showed that albumin nanoparticles were cleared more slowly and were
retained in the lung tissue to a greater extent than the equivalent dose
of albumin solution. The biocompatibility, clearance, and biodistribution
proﬁles of both albumin vehicles studied provide useful information for
formulation design by allowing researchers to model whether the use of
albumin vehicles can achieve a desired pharmacokinetic proﬁle, a suitable
administration frequency and sufﬁcient drug loading for realistic develop-
ment as an inhaled nanomedicine.
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